1. Centers for Disease Control. Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30:1–3.PMID: 6265753
2. Barré-Sinoussi F, Chermann J-C, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983; 220:868–71.
https://doi.org/10.1126/science.6189183
3. Safai B, Sarngadharan MG, Groopman JE, et al. Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet. 1984;1(8392):1438-
40.
4. Bobkov A., Cheingsong-Popov R., Selimova L., et al. An HIV Type 1 Epidemic among Injecting Drug Users in the Former Soviet Union Caused by a Homogeneous Subtype A Strain. AIDS
Res. Hum. Retroviruses. 1997;13:1195–1201.
5. UNAIDS. Global Data on HIV Epidemiology and Response; 2023. https://aidsinfo.unaids.org/. Erişim 10 Haz, 2024.
6. Joint United Nations Programme on HIV, AIDS. In danger: UNAIDS global AIDS update 2022. UN; 2022.
7. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2023 – 2022 data. Stockholm: ECDC; 2023.
8. Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. Science. 2000;287:607–14.
9. Nahmias AJ, Weiss J, Yao X, et al. Evidence for human infection with an HTLV III/LAV-like virus in Central Africa, 1959. Lancet. 1986 May 31;1(8492):1279-80.
10. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
N Engl J Med. 1987;317(4):185-91.
11. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials
Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173-80.
12. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl
J Med. 1997;337(11):734-9.
13. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med. 1996;2(6):625-9.
14. Killingley B, Pozniak A. The first once-daily single-tablet regimen for the treatment of HIV-infected patients. Drugs Today (Barc). 2007;43(7):427-42.
15. Lundgren JD, Babiker AG, Gordin F, et al.; INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
16. TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015; 373:808–22.
17. Rizzardini G, Overton ET, Orkin C, et al. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J
Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506.
18. Global Fund to Fight AIDS, Tuberculosis and Malaria. Erişim tarihi 10 Haziran 2024 https://www.theglobalfund.org/en/
19. President’s Emergency Plan for AIDS Relief (PEPFAR). Erişim tarihi 10 Haziran 2024 https://www.pepfar.gov/
20. UNAIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic. https://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf [Erişim 10 Haziran 2024] 21. UNAIDS. (2023). Global HIV & AIDS statistics—2023 fact sheet. Erişim tarihi 10 Haziran 2024 https://www.unaids.org/en/resources/fact-sheet
22. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials
Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173-80.
23. Grant RM, Lama JR, Anderson PL, et al.; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.
24. Cohen MS, Chen YQ, McCauley M, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.
25. Rodger AJ, Cambiano V, Bruun T, et al.; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is
using suppressive antiretroviral therapy. JAMA. 2016; 316:171–81.
26. Halk Sağlığı Genel Müdürlüğü. HIV/AIDS istatistikleri https://hsgm.saglik.gov.tr/depo/birimler/bulasici-hastaliklar-ve-erken-uyari-db/Dokumanlar/Istatistikler/hiv-aids-2023.pdf
27. Korten V, Gökengin D, Eren G, et al.; HIV-TR Study Group. Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of
treatment in the Turkish HIV-TR Cohort, 2011-2017. AIDS Res Ther. 2021 Ja n 9;18(1):4.
28. Yaylali E, Erdogan ZM, Calisir F, et al. Modeling the future of HIV in Turkey: Cost-effectiveness analysis of improving testing and diagnosis. PLoS One. 2023 Jun 30;18(6):e0286254.
29. Sneller MC, Blazkova J, Justement JS, et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature. 2022 Jun;606(7913):375-381.
30. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692.
31. Allers K, Hütter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 2011; 117:2791.
32. Marcus JL, Leyden WA, Alexeeff SE, et al. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. JAMA Netw
Open. 2020 Jun 1;3(6):e207954.